Efficacy of intermittent empagliflozin supplementation on dietary self‐management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24‐week randomized controlled trial

Yoshikawa, Fukumi; Kumashiro, Naoki; Shigiyama, Fumika; Uchino, Hiroshi; Ando, Yumiko; Yoshino, Hiroshi; Miyagi, Masahiko; Ikehara, Kayoko; Hirose, Takahisa

doi:10.1111/dom.13524

Cited by 3 publications

(4 citation statements)

References 51 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding was fundamentally consistent with previous studies, which indicated the beneficial effect of SGLT2 inhibitors on QOL [9][10][11][12]14]. Dapagliflozin significantly improved treatment satisfaction in an open-label, singlearm observational study, which included 221 Japanese patients with T2DM [11].…”

Section: Discussionsupporting

confidence: 91%

“…In addition, a pooled analysis of patient-reported outcomes data from four randomized controlled trials of canagliflozin, which primarily consisted of Caucasians, suggested that canagliflozin-treated patients generally showed improved health-related QOL [ 12 ]. Interestingly, Yoshikawa et al reported that even intermittent empagliflozin supplementation for 24 weeks improved treatment-related QOL in 50 patients with inadequately controlled T2DM [ 10 ]. Bolge et al evaluated the effect of canagliflozin on patient satisfaction using an internet-based questionnaire completed by healthcare providers and concluded that healthcare providers reported favorable experiences with canagliflozin and witnessed improvements in clinical outcomes and QOL of the patients [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have evaluated effect of SGLT2 inhibitors on treatment-related QOL in patients with T2DM [8][9][10][11][12][13][14]. Some of them indicated that SGLT2 inhibitors such as canagliflozin [9,12], empagliflozin [10], and dapagliflozin [11,14] were related to the improvement of treatment-related QOL in patients with type 2 diabetes, while a few of them did not clearly show the beneficial effect of the SGLT2 inhibitor on the QOL of patients [8,13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

et al. 2021

View full text Add to dashboard Cite

Introduction Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM). Methods This is the prespecified subanalysis study of the “Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)” trial. Treatment-related QOL was evaluated at baseline, week 26, week 52, and week 104 after the initiation of the study using the Diabetes Therapy-Related QOL questionnaire (DTR-QOL). Among the 340 patients in the original UTOPIA study, a total of 252 patients (127, tofogliflozin group; 125, conventional treatment group) who completed the DTR-QOL questionnaire at baseline were the study subjects of the current subanalysis. Results The tofogliflozin and conventional treatment groups exhibited almost comparable baseline clinical characteristics, while the use of antihypertensive drugs and lipid-lowering agents was significantly lower in the tofogliflozin treatment group than in the conventional treatment group. Tofogliflozin treatment increased the total score of DTR-QOL7 from baseline ( P < 0.001), while conventional treatment did not change it. There were statistically significant differences in delta change in the total DTR-QOL7 score and DTR-QOL7 Q4, Q5, Q6, and Q7 scores from the baseline to week 104 between the treatment groups. Delta changes in HbA1c (Spearman’s correlation coefficient, ρ = − 0.30, P < 0.001), fasting blood glucose ( ρ = − 0.16, P = 0.031), BMI ( ρ = − 0.19, P = 0.008), and waist circumference ( ρ = − 0.17, P = 0.024) at week 104 were negatively associated with delta change in the total QOL7 score. Conclusions Our data indicated that tofogliflozin treatment improved treatment-related QOL compared to conventional treatment in Japanese patients with T2DM, in accordance with the improvement of major cardiovascular risk factors. Trial registration: UMIN000017607 Supplementary Information The online version contains supplementary material available at 10.1007/s13300-021-01125-8.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…DTR-QOL is a diabetes-specific QOL questionnaire [25]. Previous studies have demonstrated that both SGLT2is [29,30] and DPP4is [31,32] improve scores in DTR-QOL. The results of this study showing a significant improvement in DTR-QOL scores in both groups were consistent with the findings of previous reports.…”

Section: Discussionmentioning

confidence: 99%

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)

et al. 2020

View full text Add to dashboard Cite

Introduction: No study has compared the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is) on patients' quality-of-life (QOL). Methods: We enrolled 253 drug-naïve Japanese patients with type 2 diabetes mellitus (T2DM), randomly assigned them into a dapagliflozin (SGLT2i) group or DPP4i group in approximately 1:1 ratio, and monitored them for 24 weeks. The primary endpoint was the proportion of subjects indicating improvement in the ''overall quality of life'' domain of SHIELD-WQ-9 at week 24. Secondary endpoints included other domains of SHIELD-WQ-9, DTR-QOL, EQ-5D-5L, medication preference, medication adherence, diet therapy adherence, body weight, body mass index (BMI), abdominal circumference, HbA1c, and frequency of adverse events. Results: The proportion of subjects indicating improvement in the ''overall quality of life'' domain of SHIELD-WQ-9 at week 24 was higher in the dapagliflozin group (28.4%) than in the DPP4i group (18.6%) (p = 0.08). The proportion Electronic Supplementary Material The online version of this article (

show abstract

Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia

Yoshikawa

Shigiyama

Ando

et al. 2020

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Efficacy of intermittent empagliflozin supplementation on dietary self‐management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24‐week randomized controlled trial

Abstract: Intermittent empagliflozin supplementation is a useful therapeutic option that empowers dietary self-management, improves glycaemic control and is accompanied by body weight loss and an increase in diabetes treatment-related QoL in patients with inadequately controlled type 2 diabetes.

Cited by 3 publications

References 51 publications

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)

Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia

Contact Info

Product

Resources

About